Protein Recombination Technology Enters the Market

The European Medicines Agency (EMA) has officially approved Bimervax, the COVID-19 vaccine developed by Spanish pharmaceutical company HIPRA, for use as a booster dose in individuals aged 16 and older. This vaccine utilizes a classical platform based on recombinant technology, directly introducing antigen proteins into the body to induce an immune response, rather than the mRNA approach. Specifically, it targets a dimeric protein that combines the receptor-binding domain (RBD) of the spike proteins from the Alpha and Beta variants of SARS-CoV-2. This approval holds significant clinical importance as it diversifies the vaccine supply chain, which has been largely dominated by Pfizer and Moderna's mRNA-based vaccines, and provides an alternative option based on protein recombination.

Efficacy Verified Through Immunobridging Studies

The Phase 2b/3 clinical trial (HIPRA-HH-2) for Bimervax, which served as a Phase 3 trial, involved a comparative evaluation conducted on 765 adults who had previously received an mRNA vaccine. To compare the efficacy with existing vaccines, an immunobridging approach was used to indirectly demonstrate effectiveness by measuring antibody formation levels. The clinical results showed that, compared to a booster dose of Pfizer's Comirnaty, the neutralizing antibody titers against the original Wuhan strain were lower. However, significantly higher neutralizing antibody titers were observed against the Beta and Omicron (BA.1) variants. Furthermore, it demonstrated comparable neutralizing ability against the Delta variant, proving its broad protective ability against various variants.

Enhanced Cold Chain Storage Efficiency and Logistics Advantages

Bimervax, a traditional protein recombination vaccine, significantly enhances its market competitiveness in terms of distribution and storage convenience. Unlike mRNA vaccines, which require ultra-low temperature storage at -70°C, Bimervax can be stored and distributed for extended periods at a standard refrigerated temperature of 2°C to 8°C. This feature greatly improves access to vaccination in low- and middle-income countries and rural areas with limited ultra-cold chain infrastructure, potentially addressing healthcare inequalities. Ultimately, it reduces storage costs in healthcare settings, extends the shelf life, and significantly lowers vaccine wastage.

Commercialization Strategy Focused on Public Procurement Markets

Bimervax is entering the market primarily through public procurement channels, such as the European Union's Health Emergency Response Authority (HERA), rather than through general commercial pharmacies. In 2022, it signed a joint procurement framework contract for the supply of up to 250 million doses to 14 member states. More recently, it secured an additional contract for 4 million doses of a vaccine targeting the latest circulating variant, LP.8.1. The Spanish government has invested approximately €31 million (approximately $34 million) to pre-purchase 3.2 million doses, demonstrating its price competitiveness at approximately €9.69 per dose. This is expected to lead to increased competition with similar vaccines, such as Novavax's Nuvaxovid.